Skip to main content
SpringerLink
Log in

Cisplatin: a review of clinical applications and renal toxicity

  • Review Articles
  • Published:
Pharmaceutisch Weekblad Aims and scope Submit manuscript

Abstract

In reviewing the literature about the clinical application ofcis-diamminedichloroplatinum(II) (cisplatin) it can be concluded that the availability of cisplatin has been an important advance in cancer chemotherapy; especially in patients with disseminated testicular carcinoma and ovarian cancer cisplatin-based combinations are the first choice treatment. Our own investigations of the nature of the main form of toxicity of cisplatin, the nephrotoxicity, are mentioned and methods of its prevention are summarized.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Einhorn LH, Donohue J.Cis-diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular carcinoma. Ann Intern Med 1977:87:293–8.

    PubMed  Google Scholar 

  2. Stoter G, Sleijfer DTh, Vendrik CPJ, et al. Combination chemotherapy withcis-diamminedichloroplatinum, vinblastine and bleomycin in advanced testicular non-seminoma. Lancet 1979;1:941–5.

    PubMed  Google Scholar 

  3. Stoter G, Vendrik CPJ, Struyvenberg A, et al. The 5-year survival of patients with disseminated non-seminomatous testicular cancer treated with cisplatin, vinblastine and bleomycin. Cancer 1984:54:1521–4.

    PubMed  Google Scholar 

  4. Einhorn LH, Williams SD, Troner M, Birch R, Greco FA. The role of maintenance therapy in disseminated testicular carcinoma. N Engl J Med 1981;305:727–31.

    PubMed  Google Scholar 

  5. Williams SD, Einhorn LH. Etoposide salvage therapy for refractory germ cell tumours, an update. Cancer Treat Rep 1982;9A:67–71.

    Google Scholar 

  6. Peckham MJ, Barrett A, Liew KH, et al. The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cisplatin (BEP). Br J Cancer 1983;47:613–9.

    PubMed  Google Scholar 

  7. Einhorn LH, Williams SD. Chemotherapy of disseminated seminoma. Cancer Clin Trials 1980;3:307–11.

    PubMed  Google Scholar 

  8. Neijt JP, Ten Bokkel Huinink WW, Van der Burg MEL, et al. Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5. Radiother Oncol 1984;2:19–29.

    PubMed  Google Scholar 

  9. Wiltshaw E, Kroner T. Phase II study ofcis-dichlorodiammineplatinum in advanced adenocarcinoma of the ovary. Cancer Treat Rep 1976;60:55–60.

    PubMed  Google Scholar 

  10. Neijt JP, Van der Burg MEL, Vriesendorp R, et al. Randomized trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984;2:594–600.

    PubMed  Google Scholar 

  11. Yagoda A. Chemotherapy of advanced urothelial tumours. Semin Urol 1983;1:60–74.

    PubMed  Google Scholar 

  12. Denis L. Anaphylactic reactions to repeated intravesical instillation with cisplatin. Lancet 1983;1:1378–9.

    Google Scholar 

  13. Slack NH. Results of chemotherapy protocols of the USA National Prostatic Cancer Project. Clin Oncol 1983;2:441–59.

    Google Scholar 

  14. Rossof AH, Talley RW, Stephans R, et al. Phase II evaluation ofcis-dichlorodiammineplatinum in advanced malignancies of the genito urinary and gynaecologic organs: a Southwest Oncology Group study. Cancer Treat Rep 1979;63:1557–64.

    PubMed  Google Scholar 

  15. Hall DJ, Diasio R, Goplerund DR. Cis-platinum in gynaecologic cancer. II. Squamous cell carcinoma of the cervix. Am J Obstet Gynecol 1981;141:305–8.

    PubMed  Google Scholar 

  16. Thigpen T, Shingleton H, Hansley H, Lagasse L, Blessing J. Cisplatinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 1981;48:899–903.

    PubMed  Google Scholar 

  17. Muscato MS, Perry MC, Yarbro JW. Chemotherapy of cervical carcinoma. Semin Oncol 1982;9:373–87.

    PubMed  Google Scholar 

  18. Seski JC, Edwards CL, Herson J, Rutledge FN. Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol 1982;59:225–8.

    PubMed  Google Scholar 

  19. Newlands ES. New chemotherapeutic agents in the management of gestational trophoblastic disease. Semin Oncol 1982;9:239–43.

    PubMed  Google Scholar 

  20. Hainsworth JD, Burnett LS, Jones HW, Greco FA. Resistant gestational choriocarcinoma: successful treatment with vinblastine, bleomycin and cisplatin. Cancer Treat Rep 1983;67:393–5.

    PubMed  Google Scholar 

  21. Vriesendorp R, Aalders JG, Sleijfer DTh, Willemse PHB, Bouma J, Mulder NH. Treatment of malignant germ cell tumors of the ovary with cisplatin, vinblastine and bleomycin. Cancer Treat Rep 1984;68:779–81.

    PubMed  Google Scholar 

  22. Hande KR, Des Prez RM. Chemotherapy and radiation therapy for non-small cell lung carcinoma. Clin Chest Med 1982;3:399–414.

    PubMed  Google Scholar 

  23. Hoffman PC, Bitran JD, Golomb HM. Chemotherapy of metastatic non-small cell bronchogenic carcinoma. Semin Oncol 1983;10:111–22.

    PubMed  Google Scholar 

  24. Gralla RJ, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 1981;95:414–20.

    PubMed  Google Scholar 

  25. Kelsen D, Gralla R, Stoopler M, et al. Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer. Cancer Treat Rep 1981;66:247–51.

    Google Scholar 

  26. Klastersky J, Longeval E, Nicaise C, Weerts D. Etoposide andcis-platinum in non-small-cell bronchogenic carcinoma. Cancer Treat Rev 1982;9:133–8.

    PubMed  Google Scholar 

  27. Comis RL. Small cell carcinoma of the lung. Cancer Treat Rev 1982;9:237–58.

    PubMed  Google Scholar 

  28. Cavelli F, Goldhirsch A, Siegenthaler P, Kaplan S, Beer M. Phase-II study withcis-dichlorodiammineplatinum in small cell anaplastic bronchogenic carcinoma. Eur. J Cancer 1980;16:617–21.

    PubMed  Google Scholar 

  29. Srerocki JS, Hilares BS, Hopfan S, et al.cis-dichlorodiammineplatinum and VP 16-213: An active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 1979;63:1593–7.

    PubMed  Google Scholar 

  30. Kelsen D. Treatment of advanced esophageal cancer. Cancer 1982;50:2576–31.

    PubMed  Google Scholar 

  31. Kelsen DP, Bains M, Hilaris B, et al. Combination chemotherapy of esophageal carcinoma using cisplatin, vindesine and bleomycin. Cancer 1982;49:1174–7.

    PubMed  Google Scholar 

  32. Beer M, Cocconi G, Ceci G, Varini M, Cavelli F. A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 1983;19:717–20.

    PubMed  Google Scholar 

  33. Leichman L, McDonald B, Dindogru A, Samson M, Vaitkevicius VK. Cisplatin: an active drug in the treatment of disseminated gastric cancer. Cancer 1984;53:18–22.

    PubMed  Google Scholar 

  34. Moertel C, Fleming T, O'Connell M, Schutt A, Rubin J. A phase II trial of combined intensive course 5-FU, adriamycin andcis-platinum in advanced gastric and pancreatic carcinoma. Proc Am Soc Clin Oncol 1984;3:535.

    Google Scholar 

  35. Friedman MA. The use of intravenous cisplatin in various adult malignancies. In: Prestayko AW, Crooke ST, Carter SK, eds. Cisplatin: current status and new developments. New York: Academic Press, 1980:459–64.

    Google Scholar 

  36. Ajani J, Kantargian H, Kanojia M, Karlin D. Phase II trial ofcis-platin in advanced upper gastrointestinal cancer. Proc Am Soc Clin Oncol 1984;3:573.

    Google Scholar 

  37. Kolaric K, Roth A. Phase II clinical trial ofcis-dichlorodiammineplatinum for antitumorigenic activity fn previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 1983;11:108–12.

    PubMed  Google Scholar 

  38. Cavalli F, Jungi WF, Nissen NI, Pajak TF, Coleman M, Holland JF. Phase II trial ofcis-dichlorodiammineplatinum in advanced malignant lymphoma. Cancer 1981;48:1927–30.

    PubMed  Google Scholar 

  39. Kroner T, Obrecht JP, Jungi WF. Etoposide as single agent and in combination withcis-platinum for malignant lymphomas. Cancer Treat Rev 1982;9A:39–43.

    Google Scholar 

  40. Von Heyden HW, Scherpe A, Nagel GA.Cis-dichlorodiammineplatinum and etoposide for patients with refractory lymphomas. Cancer Treat Rev 1982;9A:45–52.

    Google Scholar 

  41. Liepman MK, Wheeler RH, Zuckerman KS, Lobuglio AF. Combination chemotherapy of refractory lymphoma withcis-dichlorodiammineplatinum, vinblastine, and bleomycin. Cancer 1982;50:2736–9.

    PubMed  Google Scholar 

  42. Broun GA, Petruska PJ, Hiramoto RN, Cohen HJ. Cisplatin, BCNU, cyclophosphamide and prednison in multiple myeloma. Cancer Treat Rep 1982;66:237–42.

    PubMed  Google Scholar 

  43. Wittes RE, Cvitkovic E, Shah J, Gerold T, Strong EW.Cis-dichlorodiammineplatinum(11) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 1977;61:359–366.

    PubMed  Google Scholar 

  44. Taylor SG. Head and neck cancer. In: Pinedo HM, Chabner BA, eds. Cancer Chemotherapy 1983. Amsterdam: Elsevier Science Publishers, 1983:291–306.

    Google Scholar 

  45. Kish JA, Weaver A, Jacobs J, Cummings G, Al-Sarraf M. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 1984;53:1819–24.

    PubMed  Google Scholar 

  46. Jacobs C, Meyers F, Hendrickson C, Kohler M, Carter S. A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. Cancer 1983;52:1563–9.

    PubMed  Google Scholar 

  47. Hong WK, Schaefer S, Issell B, et al. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer 1983;52:206–10.

    PubMed  Google Scholar 

  48. Schaefer SD, Middleton R, Reisch J, Frenkel EP.Cis-platinum induction chemotherapy in the multimodality initial treatment of advanced stage IV carcinoma of the head and neck. Cancer 1983;51:2168–74.

    PubMed  Google Scholar 

  49. Decker DA, Drelichman A, Jacobs J, et al. Adjuvant chemotherapy withcis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer 1983;51:1353–5.

    PubMed  Google Scholar 

  50. Aisner J, Wiernik PH. Chemotherapy in the treatment of malignant mesothelioma. Semin Oncol 1981;8:335–43.

    PubMed  Google Scholar 

  51. Zidar BL, Pugh RP, Schiffer LM, et al. Treatment of six cases of mesothelioma with doxorubicin and cisplatin. Cancer 1983;52:1788–91.

    PubMed  Google Scholar 

  52. Karakousis CP, Holtermann OA, Holyoke ED.Cis-dichlorodiammineplatinum in metastatic soft tissue sarcomas. Cancer Treat Rep 1979;63:2071–2.

    PubMed  Google Scholar 

  53. Brenner J, Magill GB, Sordillo PP, Cheng EW, Yagoda A. Phase II trial of cisplatin in previously treated patients with advanced soft tissue sarcomas. Cancer 1982;50:2031–3.

    PubMed  Google Scholar 

  54. Stephens R, Coltman C, Rossof A, et al.Cis-dichlorodiammineplatinum in adult patients: Southwest Oncology Group studies. Cancer Treat Rep 1979;63:1609–10.

    PubMed  Google Scholar 

  55. Ochs JJ, Freeman AI, Douglass HO, Higby DS, Mindell ER, Sinks LF.Cis-dichlorodiammineplatinum in advanced osteogenic sarcoma. Cancer Treat Rep 1978;62:239–45.

    PubMed  Google Scholar 

  56. Ettinger LJ, Douglass HO, Higby DS, et al. Adjuvant adriamycin andcis-diamminedichloroplatinum in primary osteosarcoma. Cancer 1981;47:248–54.

    PubMed  Google Scholar 

  57. Jaffe N, Knapp J, Chuang VP, et al. Osteosarcoma: intra-arterial treatment of the primary tumor withcis-diamminedichloroplatinum. Cancer 1983;51:402–7.

    PubMed  Google Scholar 

  58. Al-Sarraf M, Fletcher W, Oishi N, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma. Cancer Treat Rep 1982;66:31–5.

    PubMed  Google Scholar 

  59. York RM, Lawson DH, McKay J. Treatment of metastatic malignant melanoma with vinblastine, bleomycin by infusion and cisplatin. Cancer 1983;52:2220–2.

    PubMed  Google Scholar 

  60. Nathanson L, Kaufman SD, Carey RW. Vinblastine, infusion bleomycin andcis-dichlorodiammineplatinum chemotherapy in metastatic melanoma. Cancer 1981;48:1290–4.

    PubMed  Google Scholar 

  61. Khan AB, D'Souza BJ, Wharam MD, et al. Cisplatin therapy in recurrent childhood brain tumors. Cancer Treat Rep 1982;66:2013–20.

    PubMed  Google Scholar 

  62. Howell SB, Pfeifle CE, Wung WE, Olshen RA. Intraperitonealcis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 1983;43:1426–31.

    PubMed  Google Scholar 

  63. Stark JJ, Howell SB. Nephrotoxicity ofcis-platinum (II) dichlorodiammine. Clin Pharmacol Ther 1978;23:461–6.

    PubMed  Google Scholar 

  64. Ten Bokkel Huinink WW, Hoefnagel C, Simonetti G, et al. A simple radioisotope technique for assessment of acute drug induced nephrotoxicity. Proc Am Soc Clin Oncol 1981;17:349.

    Google Scholar 

  65. Elwood CM, Sigman EM. The measurement of glomerular filtration rate and effective renal plasma flow in man by iothalamate125I and iodosyracet131. Circulation 1967;36:441–8.

    PubMed  Google Scholar 

  66. Levinsky NG, Levy M. Clearance techniques. In: Orloff J, Berliner RW, eds. Handbook of Physiology. Sect. 8. Renal Physiology. Washington DC: American Physiological Society, 1973.

    Google Scholar 

  67. Donker AJM, Van der Hem GK, Sluiter WJ, et al. A radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow. Neth J Med 1977;20:97–103.

    PubMed  Google Scholar 

  68. Meijer S, Offerman JJG, Sleijfer DTh, et al. Acute effects of infusion ofcis-diamminedichloroplatinum (CDDP) on renal function. In: Hacker MP, Douple EB, Krakoff IH, eds. Platinum coordination complexes in cancer chemotherapy. Boston: Martinus Nijhoff Publishers, 1984:203.

    Google Scholar 

  69. Offerman JJG, Meijer S, Sleijfer DTh, et al. Acute effects ofcis-diamminedichloroplatinum (CDDP) on renal function. Cancer Chemother Pharmacol 1984;12:36–8.

    PubMed  Google Scholar 

  70. Meijer S, Sleijfer DTh, Mulder NH, et al. Some effects of combination chemotherapy withcis-platinum on renal function in patients with non seminomatous testicular carcinoma. Cancer 1983;51:2035–40.

    PubMed  Google Scholar 

  71. Dentino ME, Luft FC, Yum MN, et al. Long-term effects ofcis-diamminedichloroplatinum (CDDP) on renal function and structure in man. Cancer 1978;41:1274–81.

    PubMed  Google Scholar 

  72. Jones BR, Bhalla RB, Mladek J, et al. Comparison of methods of evaluating nephrotoxicity ofcis-platinum. Clin Pharmacol Ther 1980;27:557–62.

    PubMed  Google Scholar 

  73. Flemming JJ, Collis C, Peckham MJ. Renal damage aftercis-platinum. Lancet 1979;2:961.

    Google Scholar 

  74. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979;90:929–31.

    PubMed  Google Scholar 

  75. Blachley MD, Hill JB. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 1981;95:628–32.

    PubMed  Google Scholar 

  76. Bitran JD, Debser RK, Billings AA, et al. Acute nephrotoxicity followingcis-dichlorodiammineplatinum. Cancer 1982;49:1784–8.

    PubMed  Google Scholar 

  77. Hardaker WT, Stone RA, McCoy R. Platinum nephrotoxicity. Cancer 1974;34:1030–2.

    PubMed  Google Scholar 

  78. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, et al. Pathology in clinical trials ofcis-platinum(II)diamminedichloride. Cancer 1977;39:1362–71.

    PubMed  Google Scholar 

  79. Hayes DM, Cvitkovic E, Golbey RB, et al. High dosecis-platinumdiamminedichloride. Cancer 1977;39:1372–81.

    PubMed  Google Scholar 

  80. Meijer S, Mulder NH, Sleijfer DTh, et al. Nephrotoxicity ofcis-diamminedichlorideplatinum (CDDP) during remission-induction and maintenance chemotherapy of testicular carcinoma. Cancer Chemother Pharmacol 1982;8:27–30.

    PubMed  Google Scholar 

  81. Meijer S, Mulder NH, Sleijfer DTh, et al. Influence of combination chemotherapy withcis-diamminedichloroplatinum on renal function: long-term effects. Oncology 1983;40:170–3.

    PubMed  Google Scholar 

  82. Aggarwal SK, Whitehouse MW, Ramachandran C. Ultrastructural effects of cisplatin. In: Prestayko AW, Crooke ST, Carter SK, eds. Cisplatin, current status and new developments. New York: Academic Press, 1980:79–111.

    Google Scholar 

  83. Choie DD, Longnecker DS, Del Campo AA. Acute and chronic cisplatin nephropathy in rats. Lab Invest 1981;44:397–402.

    PubMed  Google Scholar 

  84. Offerman JJG, Sleijfer DTh, Mulder NH, et al. The effect of captopril on renal function in patients during the firstcis-diamminedichloroplatinum II infusion. Cancer Chemother Pharmacol 1985;14:262–4.

    PubMed  Google Scholar 

  85. Offerman JJG, Mulder NH, Sleijfer DTh. et al. Influence of captopril oncis-diamminedichloroplatinum induced renal toxicity. Am J Nephrol (in press).

  86. Offerman JJG, Meijer S, Sleijfer DTh, et al. Calcium entry blockade with verapamil in cisplatin-treated patients. Clin Nephrol (in press).

  87. Ross AD, Gale GR. Reduction of the renal toxicity ofcis-dichlorodiammineplatinum(II) by probenecid. Cancer Treat Rep 1979;63:781–7.

    PubMed  Google Scholar 

  88. Daley-Yates PT, McBrien DC. Enhancement of cisplatin nephrotoxicity by probenecid. Cancer Rep 1984;68:445–6.

    Google Scholar 

  89. Speer RJ, Ridgweay H, Hall LM, et al. Co-ordination complexes of platinum as antitumor agents. Cancer Chemother Rep 1975;59:629–41.

    PubMed  Google Scholar 

  90. Slater TF, Ahmed J, Ibrahim SA. Studies on the nephrotoxicity ofcis-dichlorodiammineplatinum and related substances. J Clin Hematol Oncol 1977;7:534–47.

    Google Scholar 

  91. Higby DJ, Wallace Jr HJ, Bekesi JG. Reduction ofcis-dichlorodiammineplatinum II (DDP) toxicity by penicillamine (Pn) compounds in animal models and humans. Proc Am Assoc Cancer Res 1975;16:131.

    Google Scholar 

  92. Howell SB, Taetle R. Effect of sodium thiosulfate oncis-dichlorodiammineplatinum(II) toxicity and antitumor acitivity in L 1210 leukemia. Cancer Treat Rep 1980;64:611–6.

    PubMed  Google Scholar 

  93. Hayes FA, Green AA, Senzer N, et al. Tetany: A complication ofcis-dichlorodiammineplatinum(II) therapy. Cancer Treat Rep 1979;63:547–8.

    PubMed  Google Scholar 

  94. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, et al. Acute renal failure aftercis-dichlorodiammineplatinum(II) and gentamycin-cephalothin therapies. Cancer Treat Rep 1978;62:693–8.

    PubMed  Google Scholar 

  95. Salem PA, Jabboury KW, Khalik KMF. Severe nephrotoxicity: a probable complication ofcis-dichlorodiammineplatinum(II) and cephalotin-gentamycin therapy. Oncology 1982;39:31–2.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University Hospital Groningen, Oostersingel 59, 9713, EZ Groningen, The Netherlands

    Dirk Th. Sleijfer & Nanno H. Mulder

  2. Department of Nephrology, University Hospital Groningen, Oostersingel 59, 9713, EZ Groningen, The Netherlands

    Sijtze Meijer

Authors
  1. Dirk Th. Sleijfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sijtze Meijer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nanno H. Mulder
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sleijfer, D.T., Meijer, S. & Mulder, N.H. Cisplatin: a review of clinical applications and renal toxicity. Pharmaceutisch Weekblad Scientific Edition 7, 237–244 (1985). https://doi.org/10.1007/BF01959196

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01959196

Keywords

Search

Navigation